Title:
FUSION POLYPEPTIDES FOR METABOLIC DISORDERS
Document Type and Number:
WIPO Patent Application WO/2023/284822
Kind Code:
A1
Abstract:
Provided are conjugates of polypeptides comprising nanobody and FGF21 linked by a polypeptide linker. Further provided are conjugates of polypeptides comprising GLP-1, nanobody, and FGF21 linked by two polypeptide linkers respectively. Pharmaceutical compositions comprising the same and methods of treating diseases are also provided.
Inventors:
ZHANG YUANYUAN (CN)
WU BO (CN)
GUO WEI (CN)
DONG XIAONA (CN)
ZHANG YUYING (CN)
WU BO (CN)
GUO WEI (CN)
DONG XIAONA (CN)
ZHANG YUYING (CN)
Application Number:
PCT/CN2022/105686
Publication Date:
January 19, 2023
Filing Date:
July 14, 2022
Export Citation:
Assignee:
BEIJING QL BIOPHARMACEUTICAL CO LTD (CN)
International Classes:
C07K19/00; A61K39/395; A61P1/16; A61P3/04; A61P3/06; A61P3/10; A61P13/12; C07K14/435; C12N15/62; C12N15/63
Domestic Patent References:
| WO2017093465A1 | 2017-06-08 |
Foreign References:
| AU2016203044A1 | 2016-06-16 | |||
| US20090028880A1 | 2009-01-29 | |||
| US20140228546A1 | 2014-08-14 | |||
| CN110028587A | 2019-07-19 | |||
| AU2013202856A1 | 2013-05-02 |
Other References:
OMAR B. A., ANDERSEN B., HALD J., RAUN K., NISHIMURA E., AHREN B.: "Fibroblast Growth Factor 21 (FGF21) and Glucagon-Like Peptide 1 Contribute to Diabetes Resistance in Glucagon Receptor-Deficient Mice", DIABETES, AMERICAN DIABETES ASSOCIATION, US, vol. 63, no. 1, 1 January 2014 (2014-01-01), US , pages 101 - 110, XP055827617, ISSN: 0012-1797, DOI: 10.2337/db13-0710
Attorney, Agent or Firm:
JUN HE LAW OFFICES (CN)
Download PDF:
Previous Patent: CONNECTING MEMBER, BATTERY CELL AND BATTERY PACK
Next Patent: TYPE-C FEMALE ELECTRICAL CONNECTOR
Next Patent: TYPE-C FEMALE ELECTRICAL CONNECTOR